B+
Bull case
20%
Probability
Target price
$80.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
UTMD
Utah Medical ProductsCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
No-debt balance-sheet strength, substantial cash, and resilient net margin provide downside support. Successful replacement of lost customer revenue with biopharma OEM sales could restore growth.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-27.
What can break
Analyst estimate revisions, target changes, and attributed post-print market reaction are unavailable because coverage is limited.
Momentum
36
Value
61
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $72.00 · Bull $80.00 · Bear $58.00Analysis 2026-07-31; returns require an exact persisted reference.
Earnings
2026-10-27
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-31 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum36 · Δ7d -
Value61 · Δ7d +0.4
Sentiment44 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-27.
- • Value remains the lead driver in the composite, 7D delta +0.4.
Contradictions & invalidation
- • Analyst estimate revisions, target changes, and attributed post-print market reaction are unavailable because coverage is limited.
- • Higher litigation expense may persist and dilute operating earnings.
- • The post-earnings evidence is fundamentally cautious: revenue remains below prior year, replacement sales are slower than expected, neonatal and Filshie sales were weak, and litigation costs increased.
Catalyst clock
2026-10-27
Q2 earnings confirm revenue-replacement shortfall
Lead driver: Value · See fundamentals
Momentum
36
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
61
47% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.3
Sentiment
44
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 36.4 / Value 61.2 / Sentiment 43.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-31. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$58.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$235.59M
Beta
0.34
Shares Out
3.17M
P/E (TTM)
16.3
P/S (TTM)
4.78
P/FCF (TTM)
18.76
Rev YoY
-14.3%
EPS YoY
-10.2%
Gross Margin
+53.6%
Op Margin
+29.0%
Net Debt
-$85.47M
Current Ratio
48.62
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data